ISOLATION AND CHARACTERIZATION OF C-TYPE VIRAL GENE PRODUCTS OF VIRUS-NEGATIVE MOUSE CELLS by Stephenson, John R. et al.
ISOLATION  AND  CHARACTERIZATION  OF  C-TYPE  VIRAL  GENE 
PRODUCTS  OF  VIRUS-NEGATIVE  MOUSE  CELLS* 
BY JOHN  R.  STEPHENSON, STEVEN R.  TRONICK,  ROBERTA K.  REYNOLDS, 
STUART A. AARONSON 
(From the Viral Carcinogenesis Branch, National Cancer Institute, 
Bethesda, Maryland 20014) 
(Received for publication 5 November 1973) 
The  genetic  information for  RNA  C-type viruses  is  naturally  integrated 
within the DNA of mouse cells (1-4). In tissue culture, unexpressed virus can 
be activated spontaneously (5) or by treatment with different chemical inducers 
(6-8). It has recently been shown that one class of induced virus is oncogenic 
when inoculated into animals (9). Thus, the study of cellular controls over the 
expression of integrated C-type viral genes may help in determining the mech- 
anisms of development of naturally occurring cancer. 
The identification of translational products of endogenous viral genetic in- 
formation in virus-negative mouse cells would be useful in an analysis of the 
cellular restrictions to virus expression. It is known that in the absence of virus 
production, normal mouse cells contain detectable levels of an  antigen  that 
cross-reacts immunologically with  the major structural polypeptide (p30)  of 
mouse C-type viruses (10-12). However, it has yet to be shown biochemically 
that  this  activity represents  the p30 polypeptide.  Recently,  a  sensitive im- 
munologic test for another virion polypeptide, p12  (13),  has  been reported. 
Further, type-specific immunologic assays for p12 and p30 polypeptides allow 
classification of mouse  C-type viruses  into  different subgroups  (14).  In  the 
present  report, methods have been developed to purify these antigens  from 
virus-negative mouse cells. It has been possible to identify them imunologically 
and  biochemically as  virion  structural  polypeptides,  and  to  compare  their 
antigenic  specificities with  those  of known murine  leukemia  virus  (MuLV)  1 
isolates. 
Materials and Methods 
Cdls.--Liver or spleen cell suspensions were prepared from NIH Swiss mice obtained from 
colonies of the National Institutes of Health, Bethesda, Md. The continuous mouse cell lines, 
BALB/3T3 (15) and NIH/3T3 (16),  were grown  in Dulbecco's  modification  of Eagle's medium 
supplemented with 10% calf serum (Colorado  Serum Co., Denver, Colo.). 
* This work was supported in part by Contract no. NCI-E-73-3212 of the Virus Cancer 
Program of the National Cancer Institute. 
x Abbreviations used in this paper: GuHCL, guanidine hydrochloride;  Ki, Kirsten strain of 
MuLV; MuLV, murine leukemia virus; R, Rausher strain of MuLV. 
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125I-Labded C-type Virus  Polypeptides.--125Idabeled 30,000  mol  wt  (p30)  and  12,000 
mol wt (p12) antigens of the Rauseher strain (R) and  Kirsten  strain  (Ki)  of  MuLV  were 
prepared as reported previously (12-14). 
Assays.--Species-  and type-specific competitive immunoprecipitation assays for  the p30 
and p12 antigens of Ki-MuLV and R-MuLV  (14),  and the reverse transcriptase assay for 
RNA C-type virus in tissue culture fluids (17) have been described. Protein was measured by 
the method of Lowry et M. (18) using bovine serum albumin as a standard. 
Preparation of Cell Extracts.--Mouse  spleen, liver, or tissue culture ceil extracts were pre- 
pared by homogenization in 2 vol 0.01 M Tris-HC1 buffer, pH 7.8 with a Ten Broeck homoge- 
nizer (Coming Glass Works, Coming, N. Y.), followed by sonication for approximately 60 s 
at a setting of 70 with a Biosonik II sonic oscillator (Will Scientific, Inc., Rochester, N. Y.). 
The resulting extracts were treated with 2/zg/ml DNase (bovine pancrease, DNase I, Worth- 
ington Biochemical Corp., Freehold, N.J.)  at 4°C for 4 h, dialyzed overnight against 0.01 M 
Tris-HC1 (pH 7.8), and clarified by centrifugation at 3,000 rpm in an IEC PR 6000 centrifuge 
(International Equipment Co., Needham Heights, Mass.) for 30 rain. 
Viral Antigen Purification from Cell Extracts.--Cell  extracts were subjected to purification 
procedures as described below. Further details are provided in the results. 
Acid precipitation:  Around 500-1,500 mg cell extract in 100 ml 0.01 M Tris-HCl buffer was 
adjusted to pH 6.0 with 1.0 N HC1. The extract was incubated at 4°C for 1 h and the resulting 
precipitate pelleted by centrifugatinn at 30,000 rpm for 60 min in a Beckman type 30 rotor 
(Beckman Instrumeats Inc., Palo Alto,  Calif.). 
DE 52 ion exchange chromatography:  The acid-soluble fraction was exhaustively dialyzed 
against 0.01 M Tris-HC1, 1.0 mM EDTA buffer, pH 7.8 (buffer A) and applied to a 1.5 X 25 cm 
Whatman DE 52 (H. Reeve Angel & Co., Inc., Clifton, N. J.) column equilibrated with the 
same buffer. The column was washed with 100 ml buffer A and the bound proteins eluted with 
a 200-ml linear gradient of 0.0-0.4 M KC1 in buffer A. Columns were run at 4°C at a flow rate 
of 10 ml/h and 4-ml fractions collected. 
Phosphocdlulose ion  exchange chromatography:  Fractions  containing  the  appropriate 
antigenic reactivity from DE 52 columns were pooled and dialyzed against 0.01 M Imidazole, 
1.0 mM EDTA buffer, pH 6.0 (buffer B). This material was applied to a 1.5 X 25 cm phospho- 
cellulose (Whatman pll) column equilibrated with buffer B. The column was washed and the 
protein eluted as described for the DE 52 column with the exception that buffer B was used. 
Gel fdtration  chromatography:  Fractions  from  phosphocellulose  columns  were  dialyzed 
against 0.01  M  Tris-HC1 buffer, pH 8.0, lyophllized, resuspended in 0.4 ml of 6 M  guanidine 
hydrochloride (GuHC1), 0.01 M  DTT, 0.01 M  EDTA buffer, pH 8.5  (buffer C), and heated 
at 45°C for 30 rain. This material was chromatographed on an agarose (Bin Gel A-Sm, 200400 
mesh, Bio-Rad Laboratories, Richmond, Calif.) column (1.5  X  90 cm)  at  room temperature 
using buffer C as eluant at a flow  rate of 1.5 ml/h, and 1-ml fractions collected. 
RESULTS 
Purification of Viral-Specific Antigens from Normal Mouse Cells.--In attempts 
to purify viral-related antigens from cells, it was considered important to use 
methods that would not select for properties such as a molecular size or anti- 
genicity. These latter parameters could then be used in the identification of the 
purified material. Thus, in the present studies, the approach utilized was to add 
tracer  amounts  of  x25I-labeled  virion  polypeptides  to  cell  extracts,  and  to 
develop  methods  to  obtain  optimal  recovery  and  separation  of  the  labeled 
polypeptide from the bulk of the cellular protein. These procedures included 
acid precipitation and ion exchange chromatography. At each step, the recovery STEPHENSON, TRONICK, REYNOLDS, AND AARONSON  429 
of the labeled marker could then be compared with that of the corresponding 
cellular  immunologic  reactivity.  The  amounts  of  125I-labeled  polypeptide 
markers were below levels detectable by competition immunoassay. 
Partial purification of p30:  1,200 mg NIH Swiss liver cell extract was mixed 
with  12,000 cpm 125I-labeled  p30  ((5  ng protein)  and  subjected  to acid pre- 
cipitation as described in Materials and Methods. As shown in Table I, 70 % of 
the [125I]p30 but only 25 %  of the total cellular protein remained in the super- 
nate, providing a nearly threefold enrichment of [125I]p30. Portions of the  total 
and acid-soluble fractions were also assayed for mouse viral p30 antigen.  The 
results (Table I) indicate that the cellular p30 cross-reacting material showed a 
two- to threefold increase in specific activity. 
The  acid-soluble  fraction  was  subjected  to  DE  52  ion  exchange  chroma- 
tography as described in Materials and Methods. As shown in Fig. 1 A, [125I]p30 
eluted  at 0.1  M  KC1,  whereas  the protein  eluted  over a  much broader range 
with peaks at 0.05 M  and 0.13 M  KC1. Fractions 32-37, which contained the 
[~5I]p30 peak,  were pooled and  assayed for [1~5I]p30 radioactivity,  p30  cross- 
reacting material, and total protein. From the results  (Table I), it is seen that 
both [~25I]p30 and p30 cross-reacting material were enriched a  further four- to 
fivefold. When the material in these pooled fractions was subjected to phospho- 
cellulose chromatography, the a25I-label  eluted  at 0.16 M  KC1  (Fig.  1 B).  125I 
peak fractions (45-50) were pooled and assayed for [125I]p30 radioactivity, p30 
TABLE I 
Partial Purification of p30 Antigen from Mouse Cells* 
Purification  Total 
step  protein 
Cellular  p30  antigen  125I-labeled  p30 
Yield  Sp act  Yield  Sp act 
Original ex- 
tract 
Acid precipi- 
tation (pH 
6.0) 
DEAE 52 
Phosphocellu- 
lose 
Guanidine HC1 
mg  %  ng (XlO-1)/mg  %  cpm (X lO-X)/mg 
1200  100  2  100  1.0 
312  70  5.3  66  2.5 
48  35  18  40  10 
13  22  40  20  18 
0.4  7.4  492  9.3  310 
* 12,000 cpm 125I-labeled  R-MuLV p30 (<5 ng) was added to 1,200 mg NIH Swiss mouse 
liver cell extract  prepared  as described in Materials  and Methods,  adjusted  to pH 6.0, and 
centrifuged at 30,000 rpm for 90 min. p30 antigen  in the acid-soluble supernatant extract 
fraction  was purified further by DEAE 52, phosphocellulose, and agarose-GuHC1 chroma- 
tography as described in the legends to Figs. 1 and 2. Total cellular protein  concentrations 
were measured by the method of Lowry et al. (18). A heterologous intraspeeies immunoassay 
with anti-AKR-MuLV sera and 125i_labele  d R-MuLV p30 antigen was used for p30 antigen 
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FIG. 1. Partial purification of 1251-labeled RNA C-type viral polypeptides from NIH Swiss 
mouse liver cell extracts.  (A) DE 52 chromatographic analysis of [I~SI]R-MuLV p30 antigen 
(12,000 cpm) mixed with 312  mg "acid-soluble" liver cell extract as described in Materials 
and Methods.  (B)  Phosphocellulose chromatographic analysis of fractions 32-37 from (A)  as 
described in Materials and Methods. (C) DE 52 chromatography of [125I]R-MuLV p12 antigen 
(18,000 cpm) and 133 mg acid-soluble liver cell extract. (D) Phosphocellulose chromatography 
of fractions 30-37 from (C). 
cross-reacting material, and total protein. As shown in Table I, the pooled frac- 
tions were enriched a  further two- to threefold for both [125I]p30 and cellular 
p30 cross-reacting material. These sequential purification steps thus resulted 
in a  18-20-fold increase in specific activity of both 125I-labeled p30 and  un- STEPttENSON, TRONICK, REYNOLDS, AND AARONSON  431 
labeled p30 cross-reacting antigen. The fact that the enrichments of 125I-labeled 
p30 and cellular p30 cross-reacting antigen were comparable at each step of 
purification indicated that the cellular antigenic reactivity was hiochemically 
similar to the virion p30 polypeptide. 
Partial purification of p12:  Extracts of NIH Swiss mouse cells were found 
to contain barely detectable reactivity in the immunoassay for p12  antigen. 
Attempts were made to purify this antigenic activity using similar procedures 
except for the use of 125I-labeled p12 as marker. As shown in Table II, 65 % of 
the [~5I]p12, but only 25 % of the total protein in the extract remained in solu- 
tion at pH 6.0 (Table II). When analyzed by ion exchange chromatography, 
[125I]p12 eluted at 0.15 M  KC1 from DE 52 (Fig. 1 C), and in the wash-through 
TABLE II 
Partial Purification of p12 Antigen from Mouse Cells* 
Purification  Total 
step  protein 
Cellular p12 antigen  usI-labeled  p12 antigen 
Yield  Sp  act  Yield  Sp  act 
Original ex- 
tract 
Acid precipita- 
tion (pH 
6.0) 
DE 52 
Phosphocellu- 
lose 
Guanidine HC1 
mg  %  ng (XlO-X)/mg  %  ~Pm(XlO-t)/mg 
500  100  0.6  100  3.6 
133  72  1.1  78  7.5 
35  51  4.3  56  29 
2.5  35  4.9  39  33 
1.9  18  39  22  208 
* Purification procedures were performed as described for the p30 in Table I with the 
exception that a heterologous intraspecies imrnunoassay with anti-AKR-MuLV sera and 
12SI-labeled R-Mu.LV p12 antigen (14) was used for p12 antigen determinations. 
of the phosphocellulose column (Fig. 1 D). The relative enrichment of [1251]p12 
and of cell-associated pl2-1ike antigen was similar at each stage of the purifica- 
tion (Table II). These sequential procedures provided a 9-10-fold increase in 
specific activity of p12 cross-reacting antigen. 
Molecular  Weight Analysis  of Partially  Purified  Viral  Polypeptides.--The 
antigenic reactivities isolated from NIH Swiss mouse liver cells were subjected 
to agarose: GuHC1 chromatography to determine their molecular sizes.  Frac- 
tions were tested for total cellular protein, 125I radioactivity, and p30 and p12 
immunologic cross reactivities. As shown in Fig. 2, the p30-1ike cellular activity 
cochromatographed with  x~SI-labeled p30;  similarly  the  p12  antigen-like  re- 
activity and ~25I-labeled p12 antigen comigrated. From these findings, it is clear 
that the molecular weights of the cellular immunological reactivities were in- 
distinguishable from those of the corresponding viral structural polypeptides. 
In  addition,  agarose: GuHC1  chromatography provided a  further  10-20-fold 432  C-TYPE  VII(ION  POLYPEPTIDES  IN  MOUSE  CELLS 
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FIG. 2. Molecular weight analysis by agarose gel filtration chromatography of partially 
purified  cell-associated p30  and p12 polypeptides. (A) Fractions 45-50  from the phospho- 
cellulose column shown in Fig. 1 B were pooled and analyzed by agarose gel filtration chroma- 
tography in 6M GuHC1 as described in Materials and Methods. [12~i]p30 in individual frac- 
tions was measured directly in a  Packard Auto Gamma Model 5285 Scintillation Counter 
(Packard Instrument Co., Inc., Downers Grove, Ill.). Fractions were then pooled in groups 
of three, concentrated 10-fold by lyophilization, and assayed in the anti-AKR+MuLV:[125I]  - 
R-MuLV immunoassay for unlabeled p30 antigen.  (B)  Fractions 7-18 from  the phospho- 
cellulose column shown in Fig. 1 D were pooled and analyzed as described in (A) except that 
the  anti-AKR-MuLV:[t~SI]R-MuLV p12  immunoassay  was  used.  The  following proteins 
(molecular weights  in parentheses)  were used  to calibrate the gels:  bovine  serum  albumin 
(68,000), glyceraldehyde-3-phosphate  dehydrogenase  (36,000), carbonic anhydrase (29,000), 
13-1actoglobulin (18,400), and lysozyme (14,300). 
purification of each, resulting in final purifications of cellular p12  and p30 by 
50-60-fold and 2(~-300-fold, respectively (Tables I  and II). 
Analysis of Other Virus-Negative Cells  for p30 and p12 Viral Polypeptides.-- 
The above studies demonstrate the presence of two C-type viral polypeptides 
in NIH  Swiss mouse liver cells. In other studies, NIH  Swiss spleen, NIH/3T3, 
and BALB/3T3  cultures,  subjected to the same purification procedures, were STEPHENSON,  TRONICK,  REYNOLDS,  AND  AARONSON  433 
also found to contain both viral polypeptides. In contrast, purified extracts of 
African green monkey and human liver cells were nonreactive in immunoassays 
for the p30 and p12 mouse C-type viral polypeptides. The results of the above 
biochemical and immunological studies provide strong evidence that the low 
levels of immunological cross-reactivity with two virion polypeptides detected 
in normal virus-negative mouse cells represent those structural polypeptides. 
Comparison of the Levels of p30 and p12 in Normal and Virus-Infected Mouse 
Cells.--The  levels of the two viral polypeptides present in normal mouse cells 
were compared with the levels of each found in whole virions and in virus- 
producing cells. As shown in Table III, the ratio of p30-p12 in a purified prepa- 
ration of Ki-MuLV was 3.2.  A  similar ratio was detected in NIH/3T3 cells 
producing either Ki-MuLV or R-MuLV. While the levels of the two polypep- 
TABLE III 
Relatire Concentrations of p30 and p12 in Purified Virions and in Infected 
and Uninfected Mouse Cells 
Viral polypeptide concentration* 
Source  Ratio of p30/p12 
p30  p12 
ng/mg viral  or cell protein 
Ki-MuLV  1.3  X  10  ~  0.4  X  10 5  3.2 
NIH/3T3  2.2  X  10  °  7.0  X  10  -1  3.1 
NIH/3T3 (Ki-MuLV)  1.0  X  102  5.7  X  101  3.5 
NIH/3T3 (R-MuLV)  2.1  X  102  6.8  X  101  3.1 
* Quantitation of p30 and p12 was performed as described in the legends to Tables I and 
II. Results are the mean values from three sepalate determinations. 
tides in uninfected NIH/3T3 cells were considerably lower, the ratio of their 
concentrations (3.1) was comparable to that observed in whole virions. 
It was possible  to study the relative concentrations of viral-specific poly- 
peptides in normal cells and in the same cells exogenously infected with, and 
chronically producing, MuLV. At the same time, the level of virus production 
in each case was compared by reverse transcriptase  assay. This  latter assay 
provides a  measure of physical particles released into the supernate  (17). As 
shown in Table IV, with MuLV-infected NIH/3T3 and BALB/3T3 cells,  the 
ratio of virus released to the level of cell-associated p30 antigen ranged from 
53 to 75 pmol viral polymerase/ng cellular p30. In contrast, this ratio was less 
than 0.1  in uninfected NIH/3T3 or BALB/3T3 cells.  These findings suggest 
that the level of this cell-associated viral polypeptide in normal cells was dis- 
proportionately high for the amount of virus released. 
Immunological  Type  Specificities  of Partially  Purified  Cell-Associated  Viral 
Polypeptides.--It  has  been  previously  demonstrated  that  the  p30  and  p12 
polypeptides of mouse C-type viruses possess strain- or type-specific antigenic 
determinants (14). It was possible to test partially purified p30 and p12 poly- 434  C-TYPE  VIRION  POLYPEPTIDES  IN  MOUSE  CELLS 
TABLE  IV 
Relative Amounts of Cell-Associated p30 and Virus Released by Infected and 
Uninfected Mouse Calls 
pmol supernatant 
Virus released into  viralcPl~l~are~e/ng  Cells  p30/106 Cells*  supernate/24  h/106 cells~t 
total ng  pmol polymerase activity 
NIH/3T3 
Uninfected 
+Ki-MuLV 
+R-MuLV 
BALB/3T3 
Uninfected 
+ R-MuLV 
1.8  X  100  <2.0  X  10  -1  <0.1 
1.9  X  10  ~  1.0  X  104  53 
2.1  X  102  1.2  X  104  59 
1.5  X  10  o  <2.0  X  10  -1  <0.1 
1.2  X  102  9.0  X  108  75 
* Quantitation of cell-associated  p30 was performed as described in the legend to Table I. 
Results are the mean values from three separate determinations. 
~; Amount of virus in supernatant fluids was determined by methods described previously 
(17). Results are expressed as picomoles of [3H]thymidine monophosphate incorporated by 
24-h harvests of tissue culture fluids per 106 cells and are mean values from three separate 
determinations. 
peptides from NIH Swiss cells for their abilities to  compete in  type-specific 
immunoassays for R-MuLV or AKR-MuLV p30 or p12 polypeptides, and thus, 
to compare the cell-associated viral polypeptides with those of known MuLV(s). 
As shown in Fig. 3, p30 and p12 polypeptides of R-MuLV reacted preferentially 
in R-MuLV homologous immunoassays, while unlabeled p30 and p12 of AKR- 
MuLV competed preferentially in homologous assays for those components of 
AKR-MuLV. The patterns of reactivity of isolated p30 and p12 from NIH Swiss 
cells  in  corresponding  R-MuLV  and  AKR-MuLV  type-specific assays  were 
intermediate in each case (Fig. 3),  making them readily  distinguishable  from 
both R-MuLV and AKR-MuLV polypeptides. In these  same assays, the two 
polypeptides of previously studied inducible C-type viruses were indistinguish- 
able from those of AKR-MuLV  (14).  Thus,  the present findings suggest  that 
the  p30 and p12 polypeptides of NIH Swiss cells may represent components 
of a new class of endogenous C-type virus. 
DISCUSSION 
The present studies show that it is possible to achieve a marked enrichment 
of antigenic activities from normal mouse cells that cross-react with two mouse 
C-type viral polypeptides. The partially purified antigens when studied by bio- 
chemical and immunological techniques,  independent  of the methods utilized 
in their isolation,  had properties very similar to those of virion p30 and p12 
polypeptides. The fact that the recovery of viral polypeptides from normal cells 
at each step in the purification closely resembled the recovery of labeled poly- STEPHENSON~ TRONICK, REYNOLDS~ AND AARONSON  435 
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FIG. 3. Analysis of immunological type specificities of p30 and p12 polypeptides isolated 
from NIH Swiss liver cells. Reactivities of purified p30 antigens of (A) R-MuLV; (B) AKR- 
MuLV, and (C)  partially purified p30 antigen from NIH Swiss liver cells in the anti-R- 
MuLV: [I~SI]R-MuLV  p30 (O--O) and anti-AKR-MuLV:[t~SI]AKR-MuLV (O--O)  p30 
homologous intraspecies immunoassays. Reaetivities of p12 antigens of (D)  R-MuLV;  (E) 
AKR-MuLV, and (F) NIH Swiss mouse liver cells in the anti-R-MuLV:[I~SI]R-MuLV p12 
(O--O)  and  anti-AKR-MuLV:[125I]AKR-MuLV p12  (e--e)  homologous intraspecies 
immunoassays. 
peptide marker suggests that the majority of the antigenic activity is in a form 
similar to that observed in the virus. If larger precursor molecules exist, such 
as those synthesized by certain RNA viruses (19), these must either be immuno- 
logically distinct  or represent only a  minor fraction of the  total viral poly- 
peptides of the cell. 
Viral antigens were obtained from cells in sufficient quantities to allow sub- 
group classification in type-specific competition immunoassays for p30 and p12 
polypeptides (14). The patterns of reactivities of both antigens in these assays 
were similar to each other but were clearly distinct from those of either R-MuLV 
or AKR-MuLV.  Previous studies  have shown  that  two  inducible viruses  of 436  C-TYPE  VIRION  POLYPEPTIDES  IN  MOUSE  CELLS 
BALB/c mouse cells  and an inducible virus  of C58  cells,  while biologically 
distinguishable (1, 3, 17), contain p30 and p12 polypeptides that are very similar 
to those of AKR-MuLV (14).  While corresponding cell-associated viral poly- 
peptides of NIH Swiss mouse cells may be the composite of gene products of 
more than one endogenous virus, the present studies indicate that the dominant 
antigenic activities in these preparations are different from those of any other 
MuLV strain so far examined. Thus, the viral antigens of NIH Swiss cells may 
reflect those of a new class of endogenous virus. 
Recent studies indicate that NIH Swiss  mouse cells  contain C-type viral 
genetic material within their high molecular weight DNA (4). The present report 
provides  clear  evidence that  at  least  two  structural  polypeptides are  fully 
translated in  these cells  in the absence of detectable virus release.  Further, 
the ratio of intracellular concentrations of these polypeptides closely resembled 
that observed in whole virions. Thus, the cellular regulatory factors that are 
involved in restriction of complete virus expression do not lead to dispropor- 
tionate levels of either molecule. Further, the amounts of cell-associated p30 
and p12 in normal mouse cells were disproportionately high in relation to the 
amount of virus released by the cells. These findings suggest that the block to 
synthesis of endogenous NIH  Swiss  virus may involve a  replication step(s) 
other than the translation of either of these two virion polypeptides. In other 
studies in which uninfected mouse cells have been examined for the presence 
of two other virion polypeptides, the reverse transcriptase (20) and a 69,000- 
70,000 mol wt glycoprotein (21), neither has been detected. This may be due to 
differences in sensitivity of the assays or, alternatively, may reflect the existence 
of regulatory controls at the level of translation. 
The methods developed in the present  study have provided  a  50-60-fold 
purification of the p12 viral polypeptide and nearly 300-fold purification of the 
C-type viral p30  antigen from virus-negative mouse cells.  This was possible 
because  of  the  availability of  highly purified  l~6I-labeled  viral  polypeptide 
markers  and  of very sensitive immunologic techniques for detection of the 
corresponding  cell-associated  polypeptides.  While  specific  viral  polypeptide 
markers are as yet unavailable from many species,  broadly reactive and very 
sensitive immunoassays which detect all known mammalian C-type p30 antigens 
(12) have been developed. Further, using the same isolation procedures, primate 
C-type viral p30 antigens appear to behave similarly to mouse viral p30 (un- 
published observations). Thus, it may be possible to use these methods to enrich 
for C-type viral-related antigens from species in which the levels in crude cell 
extracts are presently below detection (12). 
SUMMARY 
Antigens which immunologically  cross-react  with two mouse C-type viral 
polypeptides, p30 and p12, are present at very low levels  in normal virus- 
negative mouse cells.  These two antigens have been purified  by 50-300-fold STEPI-IENSON~ TRONICK~ REYNOLDS~ AND AARONSON  437 
from  cell  extracts  and  shown  to  cochromatograph  with  the  corresponding 
labeled viral polypeptides in several systems. Their type-specific antigenicities 
are shown to be distinct from those of previously tested MuLV isolates suggest- 
ing that they may be components of a new class of endogenous C-type virus. 
The methods utilized in the present studies for concentration of virus-specific 
antigens of normal mouse cells provide an approach for detection of C-type viral 
antigens in cells of other species. 
The authors thank  Garth Anderson for helpful discussion throughout the course of this 
study and Joan Brayton for excellent technical assistance. 
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